Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.](https://figures.cochat.ai/paper-figures/f5a1d5f19b404395b158e0a3c37f4275/fosmanogepix-a-review-of-the-first-in-class-broad-spectrum-agent-for-the-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix is a first in class Gwt1 fungal protein inhibitor, which is a class of proteins necessary for mannoprotein anchoring to the cell membrane and cell wall.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, with a wide tissue distribution, high oral bioavailability, and availability in both IV and oral formulations, FMGX provides drug characteristics that are favorable for treating invasive fungal infections, such as candidemia/invasive candidiasis caused by C. auris (24, 25).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“This novel mechanism provides a broad range of activity against Candida spp. including drug-resistant Candida.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Peter, O., & Menon, A. K. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700002-jlr200 · Cited by 403
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., O’Brien, B., Chaturvedi, V., Berkow, E., Vallabhaneni, S., Forsberg, K., Chaturvedi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6901a2 · Cited by 246
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Kullberg, B. J., Viscoli, C., Pappas, P. G., Vazquez, J., Ostrosky-Zeichner, L., Rotstein, C., Sobel, J. D., Herbrecht, R., Rahav, G., Jaruratanasirikul, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy827 · Cited by 182
Zygomycosis: Reemergence of an Old Pathogen
Kauffman, C. A. (2004) · Clinical Infectious Diseases · doi:10.1086/422729 · Cited by 178
Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 8×
“Other virulence factors including adherence and germ tube formation were also examined [21].”
BackgroundMethodInfluentialZhu, Y., O’Brien, B., Leach, L., Clarke, A., Bates, M., Adams, E., Ostrowsky, B., Quinn, M., Dufort, E., Southwick, K., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01503-19 · Cited by 162
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · cited 16×
“In this model, MGX exposures were similar to those obtained in Phase 1 clinical studies, and the reduction in fungal burden in brain tissue for FMGX and FLC was 0.78 and 1.04 log10 CFU/g, respectively whereas the combination resulted in a reduction of 3.52 log10 CFU/g, suggesting possible additivity brain tissue [56].”
BackgroundMethodInfluentialIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
Self-citationTsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 135
GWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast
Umemura, M., Okamoto, M., Nakayama, K.-I., Sagane, K., Tsukahara, K., Hata, K., & Jigami, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301044200 · Cited by 127
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Self-citationMcLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115
Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age
Mercier, T., Guldentops, E., Lagrou, K., & Maertens, J. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00661 · Cited by 113
Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110 · cited 1×
“125 μg/mL, respectively, suggesting that the MGX MIC value was elevated 4-fold in the MDR strain in which there is a higher expression of efflux pumps due to the Pdr1-G1079R mutation, but not the echinocandin-resistant strain [51,52] In a study of C.”
BackgroundCastanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98
Alkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97 · cited 6×
“solani 95–2478), once daily 78 mg/kg and 104 mg/kg FMGX plus ABT significantly enhanced median survival time from 7 days to 12 and 10 days, respectively [61].”
BackgroundInfluentialSelf-citationMann, P. A., McLellan, C. A., Koseoglu, S., Si, Q., Kuzmin, E., Flattery, A. M., Harris, G. H., Sher, X., Murgolo, N., Wang, H., et al. (2014) · ACS Infectious Diseases · doi:10.1021/id5000212 · Cited by 95
Mechanisms of Candida albicans Trafficking to the Brain
Liu, Y., Mittal, R., Solis, N. V., Prasadarao, N. V., & Filler, S. G. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002305 · Cited by 93
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00178-20 · Cited by 88
Self-citationThe anti- Aspergillus drug pipeline: Is the glass half full or empty?: Table 1.
Osherov, N., & Kontoyiannis, D. P. (2016) · Medical Mycology · doi:10.1093/mmy/myw060 · Cited by 81
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., Kolamunnage-Dona, R., Schwartz, J., Kennedy, A., Law, D., et al. (2017) · mBio · doi:10.1128/mbio.01157-17 · Cited by 78
Pfaller, M. A., Duncanson, F. P., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-11 · Cited by 76
Invasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
Self-citationLocke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 70
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Kapoor, M., Moloney, M. K., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 68
Self-citationPfaller, M. A., Hata, K., Jones, R. N., Messer, S. A., Moet, G. J., & Castanheira, M. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.05.001 · Cited by 60
Arendrup, M. C., Chowdhary, A., Astvad, K. M. T., & Jørgensen, K. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-18 · Cited by 59
Viriyakosol, S., Kapoor, M., Okamoto, S., Covel, J., Soltow, Q. A., Trzoss, M., Shaw, K. J., & Fierer, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01715-18 · Cited by 59
Self-citationActivity of novel antifungal compound APX001A against a large collection of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky302 · Cited by 57
In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
Rivero-Menéndez, O., Cuenca‐Estrella, M., & Alastruey‐Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz022 · Cited by 57
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., McCarthy, D. I., Bocanegra, R. A., Olivo, M., Kirkpatrick, W. R., Everson, M. P., Duncanson, F. P., & Patterson, T. F. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03944-14 · Cited by 56
Emergence of Azole Resistance in Aspergillus
Wiederhold, N. P., & Patterson, T. F. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0035-1562894 · Cited by 56
Zhao, M., Lepak, A. J., Marchillo, K., VanHecker, J., Sánchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 53
Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50
Self-citationSynthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives
Nakamoto, K., TSUKADA, I., Tanaka, K., Matsukura, M., Haneda, T., Inoue, S., Murai, N., Abe, S., Ueda, N., Miyazaki, M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.005 · Cited by 49
Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49
Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R. S., van Marle, S. P., van Hoogdalem, E., Kramer, W. G., & Wedel, P. C. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1390 · Cited by 45
Self-citationAPX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Jeon, H. H., Gu, Y., Kapoor, M., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-18 · Cited by 43
Self-citationZhao, Y., Lee, M. H., Paderu, P., Lee, A., Jiménez‐Ortigosa, C., Park, S., Mansbach, R. S., Shaw, K. J., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-18 · Cited by 42
Self-citationEnhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Liston, S. D., Whitesell, L. J., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00261-20 · Cited by 42
Self-citationArendrup, M. C., & Jørgensen, K. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00429-20 · Cited by 41
Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1370 · Cited by 40
Self-citationBadali, H., Patterson, H. P., Sanders, C. J., Mermella, B., Gibas, C. F. C., Ibrahim, A. S., Shaw, K. J., & Wiederhold, N. P. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02343-20 · Cited by 40
Self-citationJørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33 · cited 8×
“The in vitro activity of MGX against diverse fungal species has been summarized in several publications [26,28,29].”
BackgroundMethodInfluentialMansbach, R., Shaw, K. J., Hodges, M. R., Coleman, S., & Fitzsimmons, M. E. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1209 · Cited by 21
Self-citationGebremariam, T., Alkhazraji, S., Gu, Y., Singh, S., Alqarihi, A., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01966-19 · Cited by 14
Self-citationAPX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1217 · Cited by 10
Self-citationCovel, J. A., Soltow, Q. A., Kapoor, M., Moloney, M. K., Webb, P. J., Trzoss, M., Sharp, M. D., & Shaw, K. J. (2019) · Medicinal chemistry reviews · doi:10.29200/acsmedchemrev-v54.ch10 · Cited by 7
Self-citationHuband, M. D., Pfaller, M. A., Flamm, R. K., Messer, S. A., Schaefer, B. A., Bien, P. A., & Castanheira, M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1444 · Cited by 3
Sharp, M. D., Soltow, Q. A., Shaw, K. J., & Pogliano, J. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1218 · Cited by 2
Self-citationBadali, H., Patterson, H. P., Sanders, C. J., Mermella, B., Gibas, C. F. C., Mele, J., Fan, H., Ibrahim, A. S., Shaw, K. J., & Wiederhold, N. P. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1465 · Cited by 2
Self-citationZhu, Y., Kilburn, S., Kapoor, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.02.129916 · Cited by 1
Research works printed but not linked: 4
- Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17–20). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1–1377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
- Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12–15). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1–843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA.
- Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21–24). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain.
- Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1–1378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“, short, stubby, abnormally branched hyphae) but not inhibition of growth as used for amphotericin B and the azoles [64, 100].”
BackgroundThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
The importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Thompson, G. R., & Young, J.-A. H. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027424 · Cited by 184
Metadata
- Authors
- Shaw, K. J., & Ibrahim, A. S.
- Affiliations
- Hearts Consulting Group, LLC, Poway, CA 92064, USA
- University of California, Los Angeles (US)
- Corresponding author
- Shaw, Karen Joy
- Ibrahim, Ashraf S.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-10-22
- Volume
- 6
- Issue
- 4
- Pages
- 239
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7711534
- OpenAlex
- W3093555016
- Cited by
- 229
- References
- 64
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 36 · 2023: 47 · 2022: 30 · 2021: 25
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, manogepix, invasive fungal infections, antifungal drug development, Candida, Aspergillus, echinocandin resistance, azole resistance, Scedosporium, Lomentospora prolificans, Fusarium, Mucorales, oral bioavailability, drug-drug interactions, drug tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.